New Drugs: Doripenem, raltegravir, and ixabepilone

摘要

Doripenem (Doribax-Ortho-McNeil) is the fourth carbapenem antibiotic to be marketed in the United States, joining imipenem (included in combination with cilastatin in Primaxin), meropenem (Mer-rem IV), and ertapenem (Invanz). Like its predecessors, doripenem is administered parenterally and has a broad spectrum of action that includes many aerobic and anaerobic gram-positive and gram-negative bacteria. It is highly active against gram-negative bacteria, Including Pseudomonas aeruginosa and Acinetobacter species, that are often not susceptible to, or are resistant to, other antibiotics. Imipenem and meropenem are also active against P. aeruginosa and Acinetobacter, but ertapenem has little or no activity against these bacteria.